| Primary |
| Biliary Cirrhosis Primary |
13.3% |
| Hepatic Function Abnormal |
12.6% |
| Liver Disorder |
8.9% |
| Pyrexia |
7.4% |
| Hepatitis C |
6.7% |
| Cholelithiasis |
5.9% |
| Hypertension |
5.9% |
| Hepatic Cirrhosis |
4.4% |
| Concomitant Disease Aggravated |
3.7% |
| Drug Use For Unknown Indication |
3.7% |
| Alcoholic Liver Disease |
3.0% |
| Constipation |
3.0% |
| Hepatitis |
3.0% |
| Hyperlipidaemia |
3.0% |
| Nasopharyngitis |
3.0% |
| Renal Failure |
3.0% |
| Rheumatoid Arthritis |
3.0% |
| Asthma |
2.2% |
| Autoimmune Hepatitis |
2.2% |
| Chronic Hepatitis |
2.2% |
|
| Interstitial Lung Disease |
13.7% |
| Hepatic Function Abnormal |
9.6% |
| Liver Disorder |
8.2% |
| Pyrexia |
8.2% |
| Pneumonia |
6.8% |
| Hepatic Neoplasm Malignant |
5.5% |
| Autoimmune Hepatitis |
4.1% |
| Malaise |
4.1% |
| Off Label Use |
4.1% |
| Pleural Effusion |
4.1% |
| Thrombocytopenia |
4.1% |
| Toxic Skin Eruption |
4.1% |
| Vasculitis |
4.1% |
| Cerebral Infarction |
2.7% |
| Lymphocyte Stimulation Test Positive |
2.7% |
| Melaena |
2.7% |
| Nasopharyngitis |
2.7% |
| Portal Vein Thrombosis |
2.7% |
| Stevens-johnson Syndrome |
2.7% |
| Vasculitis Necrotising |
2.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
15.6% |
| Hypertension |
10.9% |
| Product Used For Unknown Indication |
9.3% |
| Renal Transplant |
9.3% |
| Asthma |
6.1% |
| Schizophrenia |
5.9% |
| Cerebral Infarction |
5.5% |
| Gastritis |
4.6% |
| Hepatitis C |
3.2% |
| Hyperlipidaemia |
3.2% |
| Infection |
3.2% |
| Insomnia |
2.9% |
| Back Pain |
2.7% |
| Antitussive Therapy |
2.5% |
| Cardiac Failure Chronic |
2.5% |
| Cholelithiasis |
2.5% |
| Diuretic Therapy |
2.5% |
| Lumbar Spinal Stenosis |
2.5% |
| Prophylaxis |
2.5% |
| Rhinitis Allergic |
2.5% |
|
| Tracheobronchitis |
12.5% |
| Tubulointerstitial Nephritis |
9.7% |
| Toxic Epidermal Necrolysis |
6.9% |
| Generalised Oedema |
5.6% |
| Hepatic Function Abnormal |
5.6% |
| Interstitial Lung Disease |
5.6% |
| Liver Disorder |
5.6% |
| Pneumonia |
5.6% |
| Pyrexia |
5.6% |
| Sudden Cardiac Death |
5.6% |
| Anaphylactic Shock |
4.2% |
| Upper Respiratory Tract Inflammation |
4.2% |
| White Blood Cell Count Increased |
4.2% |
| Aphasia |
2.8% |
| Cholecystitis Acute |
2.8% |
| Erythema |
2.8% |
| Hyperthermia |
2.8% |
| Hypoglycaemic Encephalopathy |
2.8% |
| Incontinence |
2.8% |
| Physical Assault |
2.8% |
|
| Concomitant |
| Hepatitis C |
17.5% |
| Prophylaxis |
16.0% |
| Hypertension |
10.6% |
| Hepatic Neoplasm Malignant |
7.3% |
| Drug Use For Unknown Indication |
6.6% |
| Product Used For Unknown Indication |
6.1% |
| Rheumatoid Arthritis |
3.9% |
| Hepatic Cirrhosis |
3.7% |
| Insomnia |
3.6% |
| Gastritis |
3.0% |
| Constipation |
2.8% |
| Diabetes Mellitus |
2.5% |
| Stem Cell Transplant |
2.5% |
| Immunosuppression |
2.4% |
| Infection Prophylaxis |
2.2% |
| Hepatic Function Abnormal |
2.0% |
| Hiv Infection |
1.9% |
| Liver Disorder |
1.8% |
| Gastritis Prophylaxis |
1.8% |
| Pyrexia |
1.7% |
|
| White Blood Cell Count Decreased |
11.4% |
| Pyrexia |
8.8% |
| Renal Impairment |
8.3% |
| Rash |
6.9% |
| Platelet Count Decreased |
6.5% |
| Hepatic Function Abnormal |
6.4% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
6.3% |
| Vomiting |
4.8% |
| Liver Disorder |
4.7% |
| Sepsis |
4.6% |
| Interstitial Lung Disease |
4.5% |
| Anaemia |
4.0% |
| Pneumonia |
3.4% |
| Hepatic Neoplasm Malignant |
2.9% |
| Decreased Appetite |
2.9% |
| Renal Failure Acute |
2.8% |
| White Blood Cell Count Increased |
2.8% |
| Thrombocytopenia |
2.7% |
| Stomatitis |
2.7% |
| Hepatic Failure |
2.5% |
|
